• 1
    Simon R, Durrleman S, Hoppe RT, et al. The Non-Hodgkin Lymphoma Classification Project: long-term follow up of 1153 patients with non-Hodgkin lymphomas. Ann Intern Med. 1988; 109: 939945.
  • 2
    The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of NHL. Summary and description of a working formulation for clinical usage. Cancer. 1982; 49: 21122135.
  • 3
    Mashal RD, Cannellos GP. Small non-cleaved cell lymphoma in adults. Am J Hematol. 1991; 38: 4047.
  • 4
    Diebold J, Jaffe ES, Raphael M, Warnke RA. Burkitt lymphoma/leukemia. In: JaffeES, HarrisNL, SteinH, VardimanJW, editors. World Health Organization classification of tumours Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001: 181184.
  • 5
    Patte C, Philip T, Rodary C, et al. High survival rate in advanced stage B-cell lymphomas and leukemias without CNS involvement with a short intensive poly-chemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol. 1991; 9: 123132.
  • 6
    Soussain C, Patte C, Ostronoff M, et al. Small non-cleaved cell leukemia and lymphoma in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood. 1995; 85: 664674.
  • 7
    Hoelzer D, Ludwig W, Thiel E, et al. Improved outcome in adult B cell acute lymphoblastic leukemia. Blood. 1996; 87: 495508.
  • 8
    Lee EJ, Petroni GR, Schiffer CA, et al. Brief-duration high-intensity chemotherapy for patients with small non-cleaved cell lymphoma or FAB L3 lymphocytic leukemia: results of CALGB 9251. J Clin Oncol. 2001; 19: 40144022.
  • 9
    Kalbfleisch J, Prentice R. The statistical analysis of failure time data. New York: John Wiley & Sons, 1980.
  • 10
    The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329: 987994.
  • 11
    Murphy SB, Bowman WP, Abromowitch M, et al. Results of treatment of advanced-stage Burkitt lymphoma and B-cell acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol. 1986; 4: 17321739.
  • 12
    Schwenn MR, Blattner SR, Lynch E, Weinstein HJ. HiCOM: a two-month intensive chemotherapy regimen for children with Stage III and IV Burkitt lymphoma and B-cell acute lymphoblastic leukemia. J Clin Oncol. 1991; 9: 133138.
  • 13
    Hann IM, Eden OB, Barnes J, Pinkerton CR. MACHO chemotherapy for Stage IV B-cell lymphoma and B-cell acute lymphoblastic leukemia of childhood. Br J Haematol. 1990; 76: 359364.
  • 14
    McMaster ML, Greer JP, Greco FA, Hohnson DH, Wolff SN, Hainsworth JD. Effective treatment of small non-cleaved cell lymphoma with high-intensity brief-duration chemotherapy. J Clin Oncol. 1991; 9: 941946.
  • 15
    Mead MG, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002; 13: 12641274.
  • 16
    Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood. 1995; 85: 20252037.
  • 17
    Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996; 14: 925934.
  • 18
    Adde M, Shad A, Venzon D, et al. Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Semin Oncol. 1998; 25(2 Suppl 4 ): 3339; discussion, 45–48.
  • 19
    Reiter A, Schrappe M, Ludwig WD, et al. Favorable outcome of B cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Blood. 1992; 80: 24712478.
  • 20
    Symonds RP, McIlroy P, Khorrami J, et al. The reduction of radiation oral mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. Br J Cancer. 1996; 74: 312317.
  • 21
    Symonds RP, McIlroy P, Khorrhami J, et al. The reduction of radiation oral mucositis by selective decontamination antibiotic pastilles; a placebo controlled double blind trial. Br J Cancer. 1996; 74: 312317.
  • 22
    Dorr W, Spekl K, Farrell CL. The effect of keratinocyte growth factor on healing of manifest radiation ulcers in mouse tongue epithelium. Cell Prolif. 2002; 35 Suppl 1: 8692.
  • 23
    Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD program in Burkitt type adult acute lymphoblastic leukemia. J Clin Oncol. 1999; 17: 24612470.
  • 24
    Patte C, Auperin A, Michon J, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001; 97: 33703379.
  • 25
    Reiter A, Schrappe M, Tiemann M. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 1999; 94: 32943306.
  • 26
    Aiello A, Delia D, Fontanella E, et al. Expression of differentiation and adhesion molecules in sporadic Burkitt lymphoma. Hematol Oncol. 1990; 8: 229238.
  • 27
    Rosanda C, Cantu-Rajnoldi A, Invernizzi R, et al. B-cell acute lymphoblastic leukemia (B-ALL): a report of 17 pediatric cases. Haematologica. 1992; 77: 151155.